Back to Clinical Trials
N/ARecruiting

Screening Strategies Among High-risk Populations for Anal Cancer

Sponsored by Lisa Flowers

About this study

The goal of the proposed research is to 1) examine the performance of emerging screening methods for anal high-grade squamous intraepithelial lesion (aHSIL), a precancerous condition of anal cancer, among populations at high risk for anal cancer and 2) characterize DNA methylation, immunologic response, and environmental factors associated with aHSIL.

Anal cancer, caused by persistent infection with high-risk human papillomavirus (hrHPV), is typically preceded by anal high-grade squamous intraepithelial lesions (aHSIL). The incidence and mortality of advanced anal cancer has been increasing in the U.S., with the greatest burden of disease and mortality in individuals with chronic impairment of the immune system. The study is important because the incidence of anal cancer is particularly high among certain groups. Findings will provide much-needed evidence for anal cancer screening strategies to reduce incidence of anal cancer and improve health outcomes. The study population includes individuals with chronic impairment of the immune system and females with a known history of high-grade lower genital tract neoplasia. The study procedure…

Where this study is enrolling (2)

Who can participate

Inclusion criteria

  • ✓30-80 years of age
  • ✓Individuals with chronic impaired immune status
  • ✓History of lower genital tract neoplasia (LGTN), Zubrod Performance Status of 0-2

Exclusion criteria

  • ✕Patients treated for aHSIL less than 6 months before screening
  • ✕History of anal cancer and pregnant women.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.